Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rubella live attenuated vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac (Dalian) Vaccine Technology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
The rubella live attenuated vaccine is a viral vaccine candidate developed by Sinovac (Dalian) Vaccine Technology Co., Ltd., a joint venture between Sinovac and Jingang Group. The vaccine contains a live attenuated strain of the rubella virus designed to stimulate an active immune response, thereby providing protection against rubella infection. It has successfully completed preclinical development and is currently in Phase 1 clinical trials. The vaccine is produced at Sinovac (Dalian)'s manufacturing facilities in Dalian, China, which are equipped with production lines specifically for live attenuated vaccines. This candidate is part of a broader development strategy by Sinovac (Dalian) to establish a portfolio of live attenuated vaccines, including mumps and varicella, with the potential for future combination products such as MMR and MMRV vaccines.
- Other names
- rubella vaccinelive attenuated rubella vaccine
Beyond the preview
Go deeper on rubella live attenuated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rubella live attenuated vaccine.